Accueil   Diary - News   All news PDC*line Pharma doses first patient with high dose in ongoing PDC-LUNG-101 clinical trial with therapeutic cancer vaccine candidate (PDC*lung01) for non-small cell lung cancer

PDC*line Pharma doses first patient with high dose in ongoing PDC-LUNG-101 clinical trial with therapeutic cancer vaccine candidate (PDC*lung01) for non-small cell lung cancer

 

 

Liège, Belgium and Grenoble, France, September 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that two new cohorts have been opened in the PDC-LUNG-101 phase I/II clinical trial with its therapeutic cancer vaccine candidate PDC*lung01 for non-small cell lung cancer (NSCLC) (NCT03970746).

 

Following the completion of its first “low dose” cohort in adjuvant setting, the study’s Data Safety and Monitoring Board (DSMB) reviewed the safety data. No dose-limiting toxicity was observed. This allowed the opening of two cohorts: one assessing PDC*lung01 as a single agent in adjuvant setting at “high dose”, which already includes one patient, and one assessing PDC*lung01 at “low dose” added to the pembrolizumab monotherapy in first line Stage IV setting.

 

 

Read the press release